|Dr. Richard M. Toselli||Pres, CEO, Chief Medical Officer & Director||1.22M||N/A||1958|
|Mr. Richard C. Christopher||CFO & Treasurer||553.07k||N/A||1970|
|Dr. Robert S. Langer Jr.||Co-Founder & Member of Scientific Advisory Board||N/A||N/A||1949|
|Dr. Joseph Philip Vacanti||Co-Founder||N/A||N/A||1949|
|Mr. William D'Agostino PE||Sr. VP of Operations||N/A||N/A||N/A|
|Ms. Heather Hamel||VP of Legal Affairs & Bus. Devel. and Corp. Sec.||N/A||N/A||N/A|
|Dr. Louis Vaickus||Consultant||N/A||N/A||1953|
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The company is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for the implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
InVivo Therapeutics Holdings Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.